睿知中国疾病研究地图
候选清单0

天津天津医科大学

天津医科大学总医院

Tianjin Medical University General Hospital

在本站收录的 53 种疾病中,这家医院列在其中 29 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

天津医科大学总医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma1 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma5 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma22 篇牵头论文
  4. 胃癌Stomach cancer30 篇牵头论文
  5. 肝母细胞瘤Hepatoblastoma1 篇牵头论文
  6. 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
  7. 骨肉瘤Osteosarcoma3 篇牵头论文
  8. 胃肠道间质瘤Gastrointestinal stromal tumour2 篇牵头论文
  9. 神经母细胞瘤Neuroblastoma0 篇牵头论文
  10. 多发性骨髓瘤Multiple myeloma27 篇牵头论文牵头 1 项开放试验
  11. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia0 篇牵头论文牵头 1 项开放试验
  12. 再生障碍性贫血Aplastic anaemia23 篇牵头论文
  13. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  14. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder22 篇牵头论文牵头 2 项开放试验
  15. IgG4相关性疾病IgG4-related disease3 篇牵头论文
  16. 重症肌无力Myasthenia gravis21 篇牵头论文牵头 1 项开放试验
  17. 烟雾病Moyamoya disease2 篇牵头论文
  18. 特发性肺纤维化Idiopathic pulmonary fibrosis7 篇牵头论文
  19. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
  20. 脊髓性肌萎缩症Spinal muscular atrophy1 篇牵头论文
  21. 杜氏肌营养不良Duchenne muscular dystrophy2 篇牵头论文
  22. Alport 综合征Alport syndrome1 篇牵头论文
  23. IgA 肾病IgA nephropathy10 篇牵头论文
  24. 成骨不全症Osteogenesis imperfecta4 篇牵头论文
  25. 原发性胆汁性胆管炎Primary biliary cholangitis7 篇牵头论文
  26. 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
  27. 先天性巨结肠Hirschsprung disease0 篇牵头论文
  28. 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文
  29. Leber 遗传性视神经病变Leber hereditary optic neuropathy3 篇牵头论文

未列出的收录疾病:脊索瘤、尤文肉瘤、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、范可尼贫血、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、法布雷病、庞贝病、白塞病、戈谢病、尼曼-匹克病 C 型、先天性膈疝、遗传性大疱性表皮松解症、遗传性血管性水肿、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.04%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

天津有 2 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    分期
    II期
    开始
    2024-01
    登记号
    NCT05956587

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心临沂、南昌、天津、广州、杭州、柳州、武汉、福州、西安、郑州、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与人工智能
论文中的科室耳鼻喉/头颈外科

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 2220242025: 112025

天津有 2 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题分子标志物与基因影像与人工智能手术
论文中的科室消化/肝病科

这些论文过半是实验室或动物研究。

牵头的论文5
  1. Innovative role of the antidepressant imipramine in esophageal squamous cell carcinoma treatment: Promoting apoptosis and protective autophagy.2025International immunopharmacology
  2. Single-cell sequencing analysis reveals cancer-associated pericyte subgroup in esophageal squamous cell carcinoma to predict prognosis.2024Frontiers in immunology免费全文
  3. Early-onset esophageal squamous cell carcinoma with achalasia: A case report.2024Medicine免费全文
  4. Transgelin promotes ferroptosis to inhibit the malignant progression of esophageal squamous cell carcinoma.2023International journal of oncology免费全文
  5. Mig-6 could inhibit cell proliferation and induce apoptosis in esophageal squamous cell carcinoma.2022Thoracic cancer免费全文
中文论文(未计入)1
  1. [Ferroptosis suppressor genes are highly expressed in esophageal cancer to inhibit tumor cell ferroptosis].2024Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma已终止NCT05461794研究中心II期2022-10 启动
  2. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
PubMed 以外找到的论文(未计入)12
  1. 305P Safety and efficacy of endoscopic resection followed by adjuvant chemoradiotherapy (ERACT) for organ preservation in early-stage oesophageal squamous cell carcinoma with high-risk features: A prospective, multicenter, phase II clinical2025Annals of Oncology论文
  2. 1426P BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)2024Annals of Oncology论文
  3. Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  4. Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  5. Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  6. Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  7. Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  8. Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  9. Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  10. RETRACTED ARTICLE: Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling2022Figshare数据集
  11. 166TiP Pembrolizumab combined with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed surgery for locally advanced esophageal squamous cell carcinoma: Protocol for a multi-center, prospective, randomized-controlled, phas2021Annals of Oncology论文
  12. A Novel Potential Diagnostic and Prognostic Biomarker for Esophageal Cancer2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 22 篇,占 0.1%。

牵头论文
22
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 5520222023: 2220232024: 6620242025: 222025

天津有 4 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科病理/检验科神经外科消化/肝病科

这些论文过半是实验室或动物研究。

牵头的论文22
  1. DNASE1L3 regulates macrophage polarization through the NLRP3-GSDMD signaling pathway affecting hepatocellular carcinoma progression.2026Molecular biology of the cell
  2. Biomimetic Nanoparticles with Dual Targeting for Hepatocellular Carcinoma Promote Tumor Immune System Activation by Enhancing Extracellular ATP Homeostasis.2025ACS applied materials & interfaces
  3. LI-RADS for diagnosing hepatocellular carcinoma by contrast-enhanced US with SonoVue and Sonazoid-a single center prospective study.2025Abdominal radiology (New York)
  4. Retrospective Analysis of Aberrant Hepatic Artery in 1250 Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.2024Annali italiani di chirurgia
  5. Identification of a vascular invasion-related signature based on lncRNA pairs for predicting prognosis in hepatocellular carcinoma.2024BMC gastroenterology免费全文
  6. Overexpression of NDRG1 leads to poor prognosis in hepatocellular carcinoma through mediating immune infiltration and EMT.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  7. Identification of SPP1 + macrophages as an immune suppressor in hepatocellular carcinoma using single-cell and bulk transcriptomics.2024Frontiers in immunology免费全文
  8. Luteolin exerts anti-tumour immunity in hepatocellular carcinoma by accelerating CD8+ T lymphocyte infiltration.2024Journal of cellular and molecular medicine免费全文
  9. Nrf2/ASPM axis regulated vasculogenic mimicry formation in hepatocellular carcinoma under hypoxia.2024Journal of gastroenterology
  10. LOXL2 serves as a prognostic biomarker for hepatocellular carcinoma by mediating immune infiltration and vasculogenic mimicry.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  11. Interleukin-35 expression promotes hepatocellular carcinogenesis by inducing γδ T-cell exhaustion.2023Genomics
  12. Four-Pyroptosis Gene-Based Nomogram as a Novel Strategy for Predicting the Effect of Immunotherapy in Hepatocellular Carcinoma.2022BioMed research international免费全文
  13. Deoxyribonuclease 1-like 3 Inhibits Hepatocellular Carcinoma Progression by Inducing Apoptosis and Reprogramming Glucose Metabolism.2022International journal of biological sciences免费全文
  14. LncRNA n339260 functions in hepatocellular carcinoma progression via regulation of miRNA30e-5p/TP53INP1 expression.2022Journal of gastroenterology
  15. γδ T cells: The potential role in liver disease and implications for cancer immunotherapy.2022Journal of leukocyte biology
  16. Elevated expression of the MYB proto-oncogene like 2 (MYBL2)-encoding gene as a prognostic and predictive biomarker in human cancers.2022Mathematical biosciences and engineering : MBE
  17. DNASE1L3 arrests tumor angiogenesis by impairing the senescence-associated secretory phenotype in response to stress.2021Aging免费全文
  18. The role of different PI3K protein subtypes in the metastasis, angiogenesis and clinical prognosis of hepatocellular carcinoma.2021Annals of diagnostic pathology
  19. Long noncoding RNA TP53TG1 suppresses the growth and metastasis of hepatocellular carcinoma by regulating the PRDX4/β-catenin pathway.2021Cancer letters
  20. Pan-cancer analysis indicates that MYBL2 is associated with the prognosis and immunotherapy of multiple cancers as an oncogene.2021Cell cycle (Georgetown, Tex.)免费全文
  21. CircANKRD52 Promotes the Tumorigenesis of Hepatocellular Carcinoma by Sponging miR-497-5p and Upregulating BIRC5 Expression.2021Cell transplantation免费全文
  22. Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma.2021Clinical and experimental immunology

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 30 篇,占 0.3%。

牵头论文
30
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 9920212022: 4420222023: 5520232024: 4420242025: 772025

天津有 3 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
    分期
    III期
    开始
    2025-05
    登记号
    NCT06901531

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、成都、杭州、武汉、石家庄、福州、郑州

  2. 正在招募
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
    分期
    I期
    开始
    2022-02
    登记号
    NCT05262491

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南昌、天津、成都、杭州、济南

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与人工智能腹膜转移与晚期手术
论文中的科室普外/肝胆胰外科消化/肝病科影像/核医学科风湿免疫科
牵头的论文30
  1. CircFoxo3 knockdown inhibit gastric cancer progression by regulating Foxo3.2026In vitro cellular & developmental biology. Animal
  2. In Silico Identification and Verification of the Anticancer Mechanism of TMBM-010 from Oxytropis herba with a Rational Delivery System Design.2025ACS applied bio materials
  3. Identification of prognostic indicators for early recurrence of gastric cancer following laparoscopic gastrectomy.2025BMC surgery免费全文
  4. Tumor-Derived EBI3 Promotes CD8+ T-cell Exhaustion via STAT4-IL10/CCL5 in Gastric Cancer.2025Cancer immunology research
  5. Targeting Tumor Differentiation Grade-related Genes Prognostic Signature Including COL5A1 Based on Single-cell RNA-seq in Gastric Cancer.2025International journal of medical sciences免费全文
  6. Potential Role of EBI3 in Gastric Cancer and Its Inductive Effects on T-Cell Exhaustion.2025Journal of the American College of Surgeons
  7. Efficacy analysis of modified double band ligation-assisted endoscopic submucosal resection and endoscopic mucosal dissection in the treatment of gastric gastrointestinal stromal tumors (≤ 1.5 cm).2025Surgical endoscopy
  8. RGS4 promotes the progression of gastric cancer through the focal adhesion kinase/phosphatidyl-inositol-3-kinase/protein kinase B pathway and epithelial-mesenchymal transition.2025World journal of gastroenterology免费全文
  9. Prognostic significance of lymphovascular invasion in pN0 stage gastric cancer: a propensity score matching analysis.2024BMC surgery免费全文
  10. A competing-risk nomogram for predicting gastric cancer-specific survival in patients over 70 years: A SEER-based study.2024Cancer epidemiology
  11. Comparison of SOX and CAPOX in patients with advanced gastric cancer after laparoscopic D2 gastrectomy: A randomized controlled trial.2024Cancer medicineRCT免费全文
  12. Construction of store-operated calcium entry-related gene signature for predicting prognosis and indicates immune microenvironment infiltration in stomach adenocarcinomas.2024Scientific reports免费全文
  13. Different Methods of Minimally Invasive Esophagojejunostomy After Total Gastrectomy for Gastric Cancer: Outcomes from Two Experienced Centers.2023Annals of surgical oncology免费全文
  14. Relationship between histone demethylase LSD family and development and prognosis of gastric cancer.2023Frontiers in immunology免费全文
  15. Prognostic value and immunological roles of GPX3 in gastric cancer.2023International journal of medical sciences免费全文
  16. Efficacy of endoscopic ultrasound and endoscopic resection for esophageal schwannoma.2023Scandinavian journal of gastroenterology
  17. SMPDL3B contributes to gastric adenocarcinoma cells progression by promoting the infiltration of M2 macrophages.2023Turkish journal of medical sciences免费全文
  18. Genetic mutation and tumor microbiota determine heterogenicity of tumor immune signature: Evidence from gastric and colorectal synchronous cancers.2022Frontiers in immunology免费全文
  19. Comprehensive analysis to identify pseudogenes/lncRNAs-hsa-miR-200b-3p-COL5A2 network as a prognostic biomarker in gastric cancer.2022Hereditas免费全文
  20. CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer.2022Journal for immunotherapy of cancer免费全文
  21. Temporal heterogeneity of HER2 expression in metastatic gastric cancer: a case report.2022World journal of surgical oncology免费全文
  22. Impact of Neoadjuvant Therapy on Minimally Invasive Surgical Outcomes in Advanced Gastric Cancer: An International Propensity Score-Matched Study.2021Annals of surgical oncology
  23. A novel ferroptosis-related lncRNA signature for prognosis prediction in gastric cancer.2021BMC cancer免费全文
  24. Construction and Validation of a Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Gastric Cancer.2021Cancer control : journal of the Moffitt Cancer Center免费全文
  25. RAI14 Regulated by circNFATC3/miR-23b-3p axis Facilitates Cell Growth and Invasion in Gastric Cancer.2021Cell transplantation免费全文
  26. A comprehensive update on early gastric cancer: defining terms, etiology, and alarming risk factors.2021Expert review of gastroenterology & hepatology
  27. The Potential Role of REG Family Proteins in Inflammatory and Inflammation-Associated Diseases of the Gastrointestinal Tract.2021International journal of molecular sciences免费全文
  28. Cronkhite-Canada syndrome: An investigation in clinical features and pathogenesis.2021Journal of digestive diseases
  29. Ectopic insulinoma diagnosed by 68Ga-Exendin-4 PET/CT: A case report and review of literature.2021Medicine免费全文
  30. Primary hepatic squamous carcinoma concurrent with gastric signet ring cell carcinoma demonstrated by 18F-fluorodeoxyglucose positron emission tomography/computed tomography.2021The Korean journal of internal medicine免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
  1. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer正在招募NCT06901531研究中心III期2025-05 启动
  2. A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor正在招募NCT05262491研究中心I期2022-02 启动
  3. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  4. A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment已终止NCT04178460研究中心I期2020-02 启动
  5. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis状态不明NCT04440605研究中心2020-07 启动
  6. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  7. Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GC状态不明NCT04638959研究中心2019-09 启动
  8. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)状态不明NCT02461407研究中心II/III期2015-06 启动
  9. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

天津有 4 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

天津有 3 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 1120242025: 002025

天津有 15 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

天津有 6 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年没有牵头神经母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

天津有 11 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Neuroprotective effects of fingolimod in mouse models of Parkinson's disease.2017FASEB journal : official publication of the Federation of American Societies for Experimental Biology

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 27 篇,占 1.6%。

牵头论文
27
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 5520222023: 7720232024: 2220242025: 882025

天津有 5 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
    分期
    I/II期
    开始
    2024-11
    登记号
    NCT06911710

    年龄 18 岁 至 未注明(登记的条件)

    牵头:天津医科大学总医院天津

  2. 正在招募
    A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06083207

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、南京、南宁、天津、徐州、武汉、苏州、西安

  3. 正在招募
    Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
    分期
    未注明
    开始
    2024-12
    登记号
    NCT07028970

    年龄未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、武汉、郑州

  4. 正在招募
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
    分期
    II期
    开始
    2022-04
    登记号
    NCT05294055

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 6 家列出的医院为研究中心北京、合肥、天津、济南、郑州

  5. 正在招募
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    分期
    I/II期
    开始
    2021-09
    登记号
    NCT04973605

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南京、南昌、厦门、天津、杭州、武汉、沈阳、石家庄、福州、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题双抗与抗体药物诊断、微小残留病与危险分层干细胞移植
牵头的论文27
  1. Osteoblasts inhibit NK cell killing function via RANK/RANKL in multiple myeloma.2026Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  2. Combining PIM-2 and PARP1 Inhibitors Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells through NKG2D Binding.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements.2025Current treatment options in oncology
  4. Kaempferol induces mitophagy and disrupts iron metabolism via SFXN2 leading to apoptosis in multiple myeloma cells.2025Free radical biology & medicine
  5. Enhancing antitumor immunity via ROS-ERS and pyroptosis-induced immunogenic cell death in multiple myeloma.2025Journal for immunotherapy of cancer免费全文
  6. T-lymphocytes suppression by CD14+ monocytes with high expression of ULK2 in patients with multiple myeloma.2025Journal of translational medicine免费全文
  7. Complement C3a promotes the formation of osteoclasts by inhibiting Sirt1 to activate the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma.2025Journal of translational medicine免费全文
  8. Antitumor effect of BC12-3 on multiple myeloma via proteasome inhibition.2025Medical oncology (Northwood, London, England)
  9. A case of acute myeloid leukemia and multiple myeloma is observed to occur simultaneously.2025Medicine免费全文
  10. Targeting NKG2D/NKG2DL axis in multiple myeloma therapy.2024Cytokine & growth factor reviews
  11. Immune profiles to predict bortezomib-based treatment response for multiple myeloma patients.2024International immunopharmacology
  12. BSA-AIE Nanoparticles with Boosted ROS Generation for Immunogenic Cell Death Immunotherapy of Multiple Myeloma.2023Advanced materials (Deerfield Beach, Fla.)
  13. Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma.2023British journal of haematology
  14. An overview of pim kinase as a target in multiple myeloma.2023Cancer medicine免费全文
  15. Bone marrow-derived mesenchymal stem cells inhibit NK cell function via Tim-3/galectin-9 in multiple myeloma patients.2023Clinical and translational medicine免费全文
  16. Therapeutic strategies to enhance immune response induced by multiple myeloma cells.2023Frontiers in immunology免费全文
  17. Cellular immunity in the era of modern multiple myeloma therapy.2023International journal of cancer
  18. Study on the Effect of EZH2 Inhibitor Combined with TIGIT Monoclonal Antibody against Multiple Myeloma Cells.2023International journal of molecular sciences免费全文
  19. Tumor-associated macrophages regulate the function of cytotoxic T lymphocyte through PD-1/PD-L1 pathway in multiple myeloma.2022Cancer medicine免费全文
  20. CD155/TIGIT signalling plays a vital role in the regulation of bone marrow mesenchymal stem cell-induced natural killer-cell exhaustion in multiple myeloma.2022Clinical and translational medicine免费全文
  21. Malignant plasmacytes in bone marrow detected by flow cytometry as a predictor for the risk stratification system of multiple myeloma.2022Cytometry. Part B, Clinical cytometry
  22. Roles of LINC01473 and CD74 in osteoblasts in multiple myeloma bone disease.2022Journal of investigative medicine : the official publication of the American Federation for Clinical Research免费全文
  23. Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment.2022Leukemia research
  24. Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma.2021Clinical and experimental immunology
  25. Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients.2021Frontiers in immunology免费全文
  26. Review: Effects of anti-CD38 monoclonal antibodies on red blood cell transfusion and interventions.2021Journal of clinical laboratory analysis免费全文
  27. lncRNA MSTRG.29039.1 Promotes Proliferation by Sponging hsa-miR-12119 via JAK2/STAT3 Pathway in Multiple Myeloma.2021Oxidative medicine and cellular longevity免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)16
  1. The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors正在招募NCT06911710牵头方I/II期2024-11 启动
  2. Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection正在招募NCT07028970研究中心2024-12 启动
  3. A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma正在招募NCT06083207研究中心I/II期2024-07 启动
  4. Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma正在招募NCT05294055研究中心II期2022-04 启动
  5. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma正在招募NCT04973605研究中心I/II期2021-09 启动
  6. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT06158841研究中心III期2024-05 启动
  7. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)进行中,不再招募NCT06464991研究中心III期2024-03 启动
  8. A Study of NINLARO® in Chinese Adults With Multiple Myeloma进行中,不再招募NCT05013190研究中心2021-10 启动
  9. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)已完成NCT04939142研究中心III期2021-07 启动
  10. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05083169研究中心III期2021-10 启动
  11. A Study of Ninlaro in Real World Clinical Practice in China已完成NCT04328662研究中心2020-05 启动
  12. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)状态不明NCT03975907研究中心I/II期2019-06 启动
  13. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03860038研究中心II期2019-01 启动
  14. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动
  15. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma已完成NCT03029234研究中心III期2017-03 启动
  16. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已完成NCT03234972研究中心III期2017-11 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年没有牵头B 细胞急性淋巴细胞白血病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

天津有 3 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
    分期
    I/II期
    开始
    2024-11
    登记号
    NCT06911710

    年龄 18 岁 至 未注明(登记的条件)

    牵头:天津医科大学总医院天津

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors正在招募NCT06911710牵头方I/II期2024-11 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 23 篇,占 5.6%。

牵头论文
23
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 9920222023: 4420232024: 2220242025: 332025

天津有 2 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
研究主题免疫抑制治疗儿童干细胞移植
牵头的论文23
  1. From severe aplastic anemia with TERT variant to Wilson disease - associations or not.2025Annals of hematology免费全文
  2. Multi-omics analysis links NFKB1 activation to poor immunosuppressive therapy response in acquired aplastic anemia.2025Hematology (Amsterdam, Netherlands)
  3. Role of Macrophage TLR4 Expression in the Immunopathogenesis of Severe Aplastic Anemia.2025Journal of clinical laboratory analysis免费全文
  4. Dioscin alleviates aplastic anemia through regulatory T cells promotion.2024Hematology (Amsterdam, Netherlands)
  5. HERVs may perform as the initial trigger for acquired aplastic anemia.2024Journal of translational medicine免费全文
  6. Molecular mechanisms underlying the role of HLA-DQ in systemic immune activation in severe aplastic anemia.2023Blood cells, molecules & diseases
  7. Partial SAA patients benefit from delayed response of IST.2023Frontiers in immunology免费全文
  8. The effectiveness of a novel treatment of TIM-3(-) NK cells infusion in murine models of immune-mediated bone marrow failure.2023Journal of clinical laboratory analysis免费全文
  9. Traditional Chinese medicine for treating aplastic anemia.2023Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques免费全文
  10. Single-cell transcriptomic analysis of PB and BM NK cells from severe aplastic anaemia patients.2022Clinical and translational medicine免费全文
  11. New Trends in Nontransplant Therapy for Acquired Aplastic Anemia.2022Current pharmaceutical design
  12. Abnormal Proteomics Profile of Plasma Reveals the Immunological Pathogenesis of Severe Aplastic Anemia.2022Disease markers免费全文
  13. Dioscin Regulating Bone Marrow Apoptosis in Aplastic Anemia.2022Drug design, development and therapy免费全文
  14. A mouse model of irradiation and spleen-thymus lymphocyte infusion induced aplastic anemia.2022Hematology (Amsterdam, Netherlands)
  15. Cofilin-1 participates in the hyperfunction of myeloid dendritic cells in patients with severe aplastic anaemia.2022Journal of cellular and molecular medicine免费全文
  16. Bone marrow free immune checkpoints as a potential biomarker for differential diagnosis of acquired bone marrow failures.2022Journal of clinical laboratory analysis免费全文
  17. Identification of potential pathogenic genes for severe aplastic anemia by whole-exome sequencing.2022Journal of clinical laboratory analysis免费全文
  18. Abnormal expression of histone acetylases in CD8+ T cells of patients with severe aplastic anemia.2022Journal of clinical laboratory analysis免费全文
  19. Expression and function of SLAMF6 in CD8+ T lymphocytes of patients with severe aplastic anemia.2021Cellular immunology
  20. Clinical study on empirical and diagnostic-driven (pre-emptive) therapy of voriconazole in severe aplastic anaemia patients with invasive fungal disease after intensive immunosuppressive therapy.2021European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical MicrobiologyRCT
  21. Upregulated Expression of Profilin1 on Dendritic Cells in Patients With Severe Aplastic Anemia.2021Frontiers in immunology免费全文
  22. Myeloid dendritic cells in severe aplastic anemia patients exhibit stronger phagocytosis.2021Journal of clinical laboratory analysis免费全文
  23. Relationship between immune status after ATG treatment and PNH clone evolution in patients with severe aplastic anemia.2021Journal of clinical laboratory analysis免费全文
中文论文(未计入)11
  1. [Glucose-regulated protein 78 regulates endoplasmic reticulum stress in the pathogenesis of aplastic anemia].2025Zhonghua yi xue za zhi
  2. [Immune related pancytopenia: a new type of bone marrow failure].2025Zhonghua yi xue za zhi
  3. [Research progress on the pathogenesis of acquired aplastic anemia].2024Zhonghua nei ke za zhi
  4. [How to think about the clinical classifications of acquired aplastic anemia].2024Zhonghua yi xue za zhi
  5. [Interpretiation of guidelines for the diagnosis and management of aplastic anemia in China (2022)].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  6. [The expression and correlation analysis of TOX and inhibitory receptors on peripheral blood CD8+T cells in patients with aplastic anemia].2023Zhonghua yi xue za zhi
  7. [Abnormal expression of CXCR5+CD8+ T cells and CXCL13 in severe aplastic anemia patients and their correlation with hematological parameters].2023Zhonghua yi xue za zhi
  8. [Exclusive diagnosis of aplastic anemia].2022Zhonghua yi xue za zhi
  9. [Research Progress on Pathogenesis of Congenital Pure Red Cell Aplasia---Review].2021Zhongguo shi yan xue ye xue za zhi
  10. [Study on the loss of HLA-A allele expression in patients with aplastic anemia].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  11. [Immune regulatory effect of tacrolimus in patients with severe aplastic anemia and in murine model].2021Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia状态不明NCT02857530牵头方II期2016-08 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

天津有 3 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录
论文中的科室神经外科
牵头的论文1
  1. Molecular basis of thrombotic microangiopathy.2025Journal of thrombosis and haemostasis : JTH

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 22 篇,占 4.5%。

牵头论文
22
2021–2025 年
牵头试验
12
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 0020222023: 5520232024: 3320242025: 772025

天津有 2 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
    分期
    III期
    开始
    2026-01
    登记号
    NCT07420296

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:天津医科大学总医院天津

  2. 正在招募
    Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
    分期
    I/II期
    开始
    2025-04
    登记号
    NCT07022197

    年龄 18 岁 至 60 岁(登记的条件)

    牵头:天津医科大学总医院天津

  3. 正在招募
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06413654

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙

  4. 正在招募
    Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
    分期
    早期I期
    开始
    2022-04
    登记号
    NCT05145361

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、天津、太原、西安

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断生物制剂影像
论文中的科室神经内科影像/核医学科
牵头的论文22
  1. A real-world comparative study on the efficacy and safety of tocilizumab and rituximab in patients with neuromyelitis optica spectrum disease and myelin oligodendrocyte glycoprotein antibody-associated disease.2026Multiple sclerosis and related disorders
  2. Type I Interferon Signaling Augments Autoimmunity in Neuromyelitis Optica Spectrum Disorder.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. Changes in T lymphocyte subsets in patients with acute neuromyelitis optica spectrum disorder.2025Frontiers in immunology免费全文
  4. Astrocytes and microglia in multiple sclerosis and neuromyelitis optica.2025Handbook of clinical neurology
  5. Ofatumumab treatment in patients with neuromyelitis optica spectrum disorder: a retrospective multicenter cohort study.2025Journal of neurology
  6. Effectiveness and safety of glucocorticoids bridging rituximab in neuromyelitis spectrum disorder.2025Multiple sclerosis and related disorders
  7. Elevated levels of cerebrospinal fluid CHIT1 correlate with disease activity in neuromyelitis optica spectrum disorder.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  8. Early versus escalation treatment of tocilizumab in neuromyelitis optica spectrum disorder: a retrospective study.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  9. 4-Octyl itaconate inhibits inflammation via the NLRP3 pathway in neuromyelitis optica spectrum disorders.2024Annals of clinical and translational neurology免费全文
  10. Susceptibility-weighted image features in AQP4-negative-NMOSD versus MS.2024Multiple sclerosis and related disorders
  11. Targeting B cells in neuromyelitis optica spectrum disorder.2024The Lancet. Neurology
  12. Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder.2023Journal of neuroimmunology
  13. Rituximab induces a transient fluctuation of peripheral and follicular helper T cells in neuromyelitis optica spectrum disorder.2023Journal of neuroimmunology
  14. Bruton's tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder.2023Journal of neuroinflammation免费全文
  15. A real-world study of interleukin-6 receptor blockade in patients with neuromyelitis optica spectrum disorder.2023Journal of neurology
  16. Personalized estimates of morphometric similarity in multiple sclerosis and neuromyelitis optica spectrum disorders.2023NeuroImage. Clinical免费全文
  17. The prevalence of anti-neurofascin-155 antibodies in patients with neuromyelitis optica spectrum disorders.2021Clinical and experimental immunology
  18. Group 2 innate lymphoid cells suppress the pathology of neuromyelitis optica spectrum disorder.2021FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  19. Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder.2021Frontiers in immunology免费全文
  20. Effects of Tocilizumab Therapy on Circulating B Cells and T Helper Cells in Patients With Neuromyelitis Optica Spectrum Disorder.2021Frontiers in immunology免费全文
  21. Elevated cerebrospinal fluid β2-microglobulin levels in patients with neuromyelitis optica spectrum disorders.2021Multiple sclerosis and related disorders
  22. Cerebrospinal fluid lactate level in aquaporin-4 antibody positive neuromyelitis optica spectrum disorders: a hint on differential diagnosis and possible immunopathogenesis.2021Multiple sclerosis and related disorders
它在 ClinicalTrials.gov 上的全部试验(任何状态)15
  1. Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder正在招募NCT07420296牵头方III期2026-01 启动
  2. Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases正在招募NCT07022197牵头方I/II期2025-04 启动
  3. Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder进行中,不再招募NCT07184840牵头方II期2025-09 启动
  4. Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders已撤回NCT05909943牵头方I/II期2024-06 启动
  5. Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders进行中,不再招募NCT05792462牵头方I期2023-04 启动
  6. Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders进行中,不再招募NCT05403138牵头方II/III期2022-11 启动
  7. Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases状态不明NCT05414487牵头方2022-10 启动
  8. Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders已完成NCT05154734牵头方I/II期2021-12 启动
  9. Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders已完成NCT03350633牵头方II/III期2017-11 启动
  10. Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder已完成NCT02893111牵头方II期2015-12 启动
  11. Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders已完成NCT02249676牵头方II期2013-01 启动
  12. A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD已完成NCT03062579牵头方(推断)I/II期2017-02 启动
  13. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)正在招募NCT06413654研究中心II/III期2024-07 启动
  14. Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)正在招募NCT05145361研究中心早期I期2022-04 启动
  15. A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders进行中,不再招募NCT06044350研究中心II期2023-08 启动
PubMed 以外找到的论文(未计入)2
  1. Bone Marrow Granulopoiesis in Neuromyelitis Optica Spectrum Disorder (S32.006)2024Neurology论文
  2. Efficacy of mycophenolate mofetil for AQP4 antibody positive optic neuritis immunotherapy2022DOAJ (DOAJ: Directory of Open Access Journals)论文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.2%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

天津有 1 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。

这些数字背后的记录
研究主题诊断与鉴别治疗与复发
论文中的科室消化/肝病科风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 21 篇,占 4.2%。

牵头论文
21
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 4420222023: 2220232024: 4420242025: 552025

天津有 2 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
    分期
    I/II期
    开始
    2025-04
    登记号
    NCT07022197

    年龄 18 岁 至 60 岁(登记的条件)

    牵头:天津医科大学总医院天津

  2. 正在招募
    Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
    分期
    I期
    开始
    2025-09
    登记号
    NCT07215650

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、天津、太原、广州、成都、贵阳、郑州、长春

  3. 正在招募
    Myasthenia Gravis Registry in China
    分期
    未注明
    开始
    2024-02
    登记号
    NCT06241521

    年龄未注明(登记的条件)

    牵头:复旦大学附属华山医院;另有 15 家列出的医院为研究中心上海、北京、南昌、天津、广州、徐州、成都、苏州、西安、郑州、重庆、长春、长沙

  4. 正在招募
    Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
    分期
    II期
    开始
    2022-07
    登记号
    NCT05067348

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:空军军医大学唐都医院;另有 5 家列出的医院为研究中心上海、北京、天津、成都、西安、长沙

  5. 正在招募
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    分期
    III期
    开始
    2021-07
    登记号
    NCT04951622

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、济南、福州、西安、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题胸腺与胸腺切除抗体与诊断生物制剂与补体抑制剂
论文中的科室神经内科
牵头的论文21
  1. The prognosis of MG patients with different thymic pathology: a multicenter retrospective cohort study.2025BMC medicine免费全文
  2. Single-cell atlas reveals heterogeneous response to FcRn blockade in anti-AChR antibody-positive generalised myasthenia gravis.2025Clinical and translational medicine免费全文
  3. Treatment strategy for myasthenia gravis with GAD65-IgG associated neurological disorders: A case report.2025Journal of neuroimmunology
  4. Outcomes in Relation to the Age at Onset in Patients With Myasthenia Gravis.2025Neurology
  5. The role of regulatory B cell/T follicular helper cell balance in thymoma and thymoma-associated myasthenia gravis.2025Scientific reports免费全文
  6. Responsiveness to Tocilizumab in Anti-Acetylcholine Receptor-Positive Generalized Myasthenia Gravis.2024Aging and disease免费全文
  7. Clinical features of COVID-19 infection in patients with myasthenia gravis: a real-world retrospective study.2024Frontiers in public health免费全文
  8. Serum amyloid A facilitates expansion of CD4+ T cell and CD19+ B cell subsets implicated in the severity of myasthenia gravis patients.2024Journal of neurochemistry
  9. Distribution of multi-level B cell subsets in thymoma and thymoma-associated myasthenia gravis.2024Scientific reports免费全文
  10. Thymectomy in thymomatous generalized myasthenia gravis: An analysis of the prognosis and risk factors.2023European journal of neurology
  11. TLR4-MyD88-NF-κB signaling imbalances Th17 and Treg cells in thymoma with myasthenia gravis.2023European review for medical and pharmacological sciences
  12. Expression of TRAF6 in peripheral blood B cells of patients with myasthenia gravis.2022BMC neurology免费全文
  13. Roles of IL-35-producing T and B cells in anti-acetylcholine receptor antibody-positive myasthenia gravis.2022Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  14. Serum irisin levels in patients with myasthenia gravis.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  15. Thymectomy in ocular myasthenia gravis-prognosis and risk factors analysis.2022Orphanet journal of rare diseases免费全文
  16. Two types of immune infiltrating cells and six hub genes can predict the occurrence of myasthenia gravis in patients with thymoma.2021Bioengineered免费全文
  17. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis.2021Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  18. Increased serum IL-27 concentrations and IL-27-producing cells in MG patients with positive AChR-Ab.2021Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  19. Low-dose rituximab treatment for new-onset generalized myasthenia gravis.2021Journal of neuroimmunology
  20. Imbalance of Th17 and Tregs in thymoma may be a pathological mechanism of myasthenia gravis.2021Molecular immunology
  21. Effects of thymectomy on late-onset non-thymomatous myasthenia gravis: systematic review and meta-analysis.2021Orphanet journal of rare diseases免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
  1. Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases正在招募NCT07022197牵头方I/II期2025-04 启动
  2. The Specificity, Sensitivity and Clinical Correlation of CBA, RIPA and ELISA in Detecting AChR and MuSK IgG of Myasthenia Gravis已完成NCT05219097牵头方2021-01 启动
  3. Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)正在招募NCT07215650研究中心I期2025-09 启动
  4. Myasthenia Gravis Registry in China正在招募NCT06241521研究中心2024-02 启动
  5. Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis正在招募NCT05067348研究中心II期2022-07 启动
  6. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis正在招募NCT04951622研究中心III期2021-07 启动
  7. Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis状态不明NCT05716035研究中心II/III期2023-04 启动
  8. A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis已终止NCT04963270研究中心III期2021-10 启动
  9. A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis进行中,不再招募NCT05070858研究中心III期2021-12 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.6%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

天津有 2 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。

这些数字背后的记录
研究主题影像与脑血流中风与出血儿童
论文中的科室影像/核医学科神经外科
牵头的论文2
  1. Three-Dimensional Arterial Spin Labeling for the Evaluation of the Cerebral Hemodynamics in Ischemic and Hemorrhagic Moyamoya Disease.2024Cerebrovascular diseases (Basel, Switzerland)
  2. Risk factors of rupture and mortality for intracranial aneurysms associated with moyamoya disease: a multicenter retrospective study.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
PubMed 以外找到的论文(未计入)1
  1. Impact of superficial temporal artery⁃middle cerebral artery bypass combined with encephalo⁃myo⁃synangiosis on cognitive function in patients with moyamoya disease2022DOAJ (DOAJ: Directory of Open Access Journals)论文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.7%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 1120232024: 0020242025: 442025

天津有 12 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙

  2. 正在招募
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
    分期
    II期
    开始
    2025-11
    登记号
    NCT07121413

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、南京、南昌、呼和浩特、天津、广州、徐州、成都、杭州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文7
  1. Roflumilast mitigates idiopathic pulmonary fibrosis via inhibition of iron accumulation and ferroptosis.2025European journal of pharmacology
  2. The histone demethylase KDM6B links obstructive sleep apnea to idiopathic pulmonary fibrosis.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  3. Identification and validation of CDC20 and ITCH as ubiquitination related biomarker in idiopathic pulmonary fibrosis.2025Hereditas
  4. Add-On Dextromethorphan Improves the Effects of Pirfenidone in Bleomycin-Treated Mice and Patients With Pulmonary Fibrosis.2025Respirology (Carlton, Vic.)
  5. Potential biomarkers for diagnosis and disease evaluation of idiopathic pulmonary fibrosis.2023Chinese medical journal
  6. Identification of autophagy-related genes in idiopathic pulmonary fibrosis using bioinformatics methods.2021Chinese medical journal
  7. Role of various imbalances centered on alveolar epithelial cell/fibroblast apoptosis imbalance in the pathogenesis of idiopathic pulmonary fibrosis.2021Chinese medical journal
它在 ClinicalTrials.gov 上的全部试验(任何状态)13
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)正在招募NCT07687459研究中心III期2026-09 启动
  2. A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis正在招募NCT07121413研究中心II期2025-11 启动
  3. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis即将招募NCT07131150研究中心II期2025-08 启动
  4. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast进行中,不再招募NCT06238622研究中心III期2024-09 启动
  5. A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis已终止NCT06360094研究中心II期2024-08 启动
  6. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT06335303研究中心II期2024-09 启动
  7. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis已终止NCT06097260研究中心II期2023-11 启动
  8. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT05938920研究中心II期2023-06 启动
  9. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT05321069研究中心III期2022-10 启动
  10. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis已终止NCT04552899研究中心III期2021-03 启动
  11. A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis已终止NCT04594707研究中心III期2021-08 启动
  12. Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)已终止NCT04419558研究中心III期2020-09 启动
  13. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)已终止NCT03955146研究中心III期2019-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

天津有 5 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科
牵头的论文1
  1. DNA nanoflower Oligo-PROTAC for targeted degradation of FUS to treat neurodegenerative diseases.2025Nature communications
早期论文(2016–2020 年)3
  1. Triple Stimulation Technique in Amyotrophic Lateral Sclerosis.2019Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society
  2. Neurofilament Subunit L Levels in the Cerebrospinal Fluid and Serum of Patients with Amyotrophic Lateral Sclerosis.2018Neuro-degenerative diseases
  3. The emerging link between O-GlcNAcylation and neurological disorders.2017Cellular and molecular life sciences : CMLS

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊髓性肌萎缩症

Spinal muscular atrophy

2021–2025 年中国大陆作者发表的 55 篇脊髓性肌萎缩症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.8%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

天津有 1 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊髓性肌萎缩症开放试验。

这些数字背后的记录
牵头的论文1
  1. Pregnancy and delivery in a woman with spinal muscular atrophy type III.2025European journal of obstetrics, gynecology, and reproductive biology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

天津有 4 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
论文中的科室病理/检验科神经内科
牵头的论文2
  1. Upregulation of Wilms' Tumor 1 in epicardial cells increases cardiac fibrosis in dystrophic mice.2022Cell death and differentiation
  2. Exosome-mediated improvement in membrane integrity and muscle function in dystrophic mice.2021Molecular therapy : the journal of the American Society of Gene Therapy

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年中国大陆作者发表的 58 篇Alport 综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

天津有 1 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 10 篇,占 1.4%。

牵头论文
10
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 4420232024: 2220242025: 222025

天津有 6 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
    分期
    II期
    开始
    2026-05
    登记号
    NCT07614477

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、天津

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肾内科
牵头的论文10
  1. The neutrophil-to-monocyte ratio: a superior inflammatory marker predicting poor prognosis in IgA nephropathy.2025BMC nephrology
  2. Increased soluble CD16b derived from activated neutrophils in plasma is associated with the pathogenesis and progression of IgA nephropathy.2025International immunopharmacology
  3. Clinical and pathological findings of IgA nephropathy following SARS-CoV-2 infection.2024Clinical and experimental medicine
  4. Prognosis of IgA Nephropathy with Stages 3b-5 CKD.2024Kidney & blood pressure research
  5. The effect of fibrinoid necrosis on the clinical features and outcomes of primary IgA nephropathy.2023BMC nephrology
  6. Deciphering prognostic value of CD22 and its contribution to suppression of proinflammatory cytokines production in patients with IgA nephropathy.2023Immunology letters
  7. Effect of hematuria on the kidney disease progression in IgA nephropathy patients with mild proteinuria and well-preserved renal function.2023International immunopharmacology
  8. Circulating platelets supply ST6Gal-1 in patients with IgA nephropathy.2023Postgraduate medicine
  9. The difference between patients with nephrotic syndrome and nephrotic-range proteinuria in IgA nephropathy: a propensity score matched cohort study.2022BMC nephrology
  10. Sialylation of IgG inhibits the formation of galactose-deficient IgA1-containing immune complexes and protects mesangial cells from injury in IgA nephropathy.2022BMC nephrology
早期论文(2016–2020 年)9
  1. A case presentation of an IgA nephropathy patient with Vogt-Koyanagi-Harada syndrome.2020BMC nephrology
  2. C1GALT1 expression is associated with galactosylation of IgA1 in peripheral B lymphocyte in immunoglobulin a nephropathy.2020BMC nephrology
  3. ST6Gal1 is up-regulated and associated with aberrant IgA1 glycosylation in IgA nephropathy: An integrated analysis of the transcriptome.2020Journal of cellular and molecular medicine
  4. ELL2 Is Downregulated and Associated with Galactose-Deficient IgA1 in IgA Nephropathy.2019Disease markers
  5. Comprehensive analysis of aberrantly expressed profiles of mRNA and its relationship with serum galactose-deficient IgA1 level in IgA nephropathy.2019Journal of translational medicine
  6. Clinical Significance of Galactose-Deficient IgA1 by KM55 in Patients with IgA Nephropathy.2019Kidney & blood pressure research
  7. Changes E3 ubiquitin protein ligase 1 gene mRNA expression correlated with IgA1 glycosylation in patients with IgA nephropathy.2019Renal failure
  8. Corticosteroid for IgA Nephropathy: Are They Really Therapeutic?2018American journal of nephrology
  9. A Systematic Review and Meta-Analysis of Kidney and Pregnancy Outcomes in IgA Nephropathy.2016American journal of nephrology
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases正在招募NCT07614477研究中心II期2026-05 启动
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年中国大陆作者发表的 99 篇成骨不全症 PubMed 英文论文中,这家医院牵头了 4 篇,占 4.0%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 2220242025: 002025

天津有 2 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 7 篇,占 2.3%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 2220242025: 332025

天津有 5 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    分期
    III期
    开始
    2025-12
    登记号
    NCT07282353

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心Baoji、上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
    分期
    II/III期
    开始
    2023-02
    登记号
    NCT05749822

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院;另有 11 家列出的医院为研究中心Yan’an、北京、南京、天津、广州、成都、昆明、沈阳、西安、郑州、长沙

  3. 正在招募
    Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
    分期
    III期
    开始
    2023-02
    登记号
    NCT05751967

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院;另有 6 家列出的医院为研究中心兰州、南京、天津、广州、成都、沈阳、西安

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科
牵头的论文7
  1. The Depletion of Plasma Cells but Not CD20+B Cells Alleviates Primary Biliary Cholangitis.2025Liver international : official journal of the International Association for the Study of the Liver
  2. Characterisation and Clinical Relevance of Tertiary Lymphoid Structures in Primary Biliary Cholangitis.2025Liver international : official journal of the International Association for the Study of the Liver
  3. Lactococcus garvieae aggravates cholestatic liver disease by increasing intestinal permeability and enhancing bile acid reabsorption.2025World journal of gastroenterology
  4. Associations between sleep disorders and clinical outcomes of patients with primary biliary cholangitis.2024Advances in medical sciences
  5. Depressive symptom as a risk factor for cirrhosis in patients with primary biliary cholangitis: Analysis based on Lasso-logistic regression and decision tree models.2024Brain and behavior
  6. Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms.2023Annals of hepatology
  7. Novel HLA-DRB1 alleles contribute risk for disease susceptibility in primary biliary cholangitis.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
中文论文(未计入)2
  1. [Clinical characteristics and risk factors for disease progression in patients with anti-gp210 antibody-positive primary biliary cholangitis].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  2. [Research progress on clinical features and pathogenesis of anti-gp210-positive primary biliary cholangitis].2024Zhonghua nei ke za zhi
早期论文(2016–2020 年)2
  1. [Characteristics of initial diagnosis in autoimmune liver disease: an 18-year, retrospective single-center study].2019Zhonghua nei ke za zhi
  2. miR-181a regulates Th17 cells distribution via up-regulated BCL-2 in primary biliary cholangitis.2018International immunopharmacology
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA正在招募NCT07282353研究中心III期2025-12 启动
  2. Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis正在招募NCT05749822研究中心II/III期2023-02 启动
  3. Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis正在招募NCT05751967研究中心III期2023-02 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

天津有 2 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    分期
    III期
    开始
    2026-05
    登记号
    NCT07387549

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、天津、广州、济南、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年没有牵头先天性巨结肠的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

天津有 2 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

天津有 2 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Leber 遗传性视神经病变

Leber hereditary optic neuropathy

2021–2025 年中国大陆作者发表的 52 篇Leber 遗传性视神经病变 PubMed 英文论文中,这家医院牵头了 3 篇,占 5.8%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 1120232024: 0020242025: 002025

天津有 1 家医院列在Leber 遗传性视神经病变下全国有 32 家医院列在Leber 遗传性视神经病变下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

天津医科大学总医院

Tianjin Medical University General Hospital

天津

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
General Hospital of Tianjin Medical University; Tianjin General Hospital; Tianjin Medical University General Hospital Airport Site; Binhai Hospital of Tianjin Medical University General Hospital; Tianjin Medical University General HospitalTianjinP.R. China; Tianjin Medical University General Hospital Airport Hospital; Tianjin Medical University General hospital; Tianjin Medical University General Hospital Hospital

提出更正下载数据